Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574 is registered in ClinicalTrials.gov with Scancell Ltd as lead sponsor.

NCT NCT07815574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Lead sponsor
Scancell Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2032
Enrollment
550 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, melanoma (skin cancer), metastatic melanoma, skin cancer